Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig

M. Kremer, Joel; Westhovens, René; Léon, Marc; Di Giorgio, Eduardo; Alten, Rieke; Steinfeld, Serge; S. Russell, Anthony; Dougados, Maxime; Emery, Paul; Nuamah, Isaac; Williams, Glennis; Becker, Jean‐Claude; Hagerty, David; W. Moreland, Larry

doi:10.1056/nejmoa035075

Public

Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig

Published in New England Journal of Medicine • Nov 12, 2003

Authors:

Joel M. Kremer

René Westhovens

Marc Léon

Abstract

BACKGROUND: Effective new therapies are needed for rheumatoid arthritis. Current therapies target the products of activated macrophages; however, T cells also have an important role in rheumatoid arthritis. A fusion protein--cytotoxic T-lymphocyte-associated antigen 4-IgG1 (CTLA4Ig)--is the first in...

Subject

Medicine

Rheumatoid arthritis

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!